About Stemline Therapeutics
Stemline Therapeutics is a company based in New York (United States) founded in 2003 by Ivan Bergstein was acquired by Menarini in May 2020. It operates as a Direct-to-Consumer (D2C). Stemline Therapeutics has raised $15.09 million across 4 funding rounds from investors including Pequot Capital Management and Menarini Group. The company has 131 employees as of December 31, 2022. Stemline Therapeutics has completed 1 acquisition, including Primrose Therapeutics. Stemline Therapeutics offers products and services including ELZONRIS and ORSERDU. Stemline Therapeutics operates in a competitive market with competitors including Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
- Headquarter New York, United States
- Employees 131 as on 31 Dec, 2022
- Founders Ivan Bergstein
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stemline Therapeutics, Inc.
-
Annual Revenue
$898.2 K (USD)0as on Dec 31, 2017
-
Net Profit
-$76.82 M (USD)10as on Dec 31, 2019
-
EBITDA
-$79.25 M (USD)8as on Dec 31, 2019
-
Total Equity Funding
$15.09 M (USD)
in 4 rounds
-
Latest Funding Round
$740 K (USD), Series A
Jan 17, 2012
-
Investors
Pequot Capital Management
& 1 more
-
Employee Count
131
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Menarini
(May 04, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Stemline Therapeutics
Stemline Therapeutics offers a comprehensive portfolio of products and services, including ELZONRIS and ORSERDU.
Used for treating blastic plasmacytoid dendritic cell neoplasm.
Indicated for ER-positive, HER2-negative advanced breast cancer.
People of Stemline Therapeutics
Unlock access to complete
Leadership Team
51 people
Software Development Team
32 people
Sales and Marketing
22 people
Medical Team
12 people
Senior Team
9 people
Operations Team
9 people
Legal and Compliance
8 people
Product Management Team
5 people
Unlock access to complete
Funding Insights of Stemline Therapeutics
Stemline Therapeutics has successfully raised a total of $15.09M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $740 thousand completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stemline Therapeutics
Stemline Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Pequot Capital Management and Menarini Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Menarini Group is engaged in pharmaceutical and healthcare solutions.
|
Locked | Locked | Locked |
Investor details for Stemline Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stemline Therapeutics
Stemline Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Primrose Therapeutics.
Investment portfolio details for Stemline Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD)
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for Stemline Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Stemline Therapeutics
Detailed financials for Stemline Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stemline Therapeutics Comparisons
Peer comparison for Stemline Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stemline Therapeutics
Stemline Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Ossium Health is focused on bioengineering for improved health.
|
|
| Locked | Locked | Locked |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for hematopoietic stem cell transplants are developed.
|
Detailed competitors of Stemline Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stemline Therapeutics
Complete news archive for Stemline Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stemline Therapeutics
Stemline Therapeutics was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Stemline Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Ivan Bergstein is the current CEO of Stemline Therapeutics. They have also founded this company.
Stemline Therapeutics is a funded company, having raised a total of $15.09M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Stemline Therapeutics is 131.
Annual revenue of Stemline Therapeutics is $898.2K as on Dec 31, 2017.
Stemline Therapeutics, part of the Menarini Group, is dedicated to the development of innovative therapies in oncology. The company focuses on transforming the lives of cancer patients through a broad pipeline of transformative treatments. Their key products include ELZONRIS for blastic plasmacytoid dendritic cell neoplasm and ORSERDU for advanced breast cancer. Operations are centered in therapeutic areas with high unmet needs, contributing to advancements in cancer care.
Stemline Therapeutics's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Stemline Therapeutics offers ELZONRIS and ORSERDU.
Stemline Therapeutics has made 1 acquisition, including Primrose Therapeutics.
Stemline Therapeutics has 2 investors. Key investors include Pequot Capital Management, and Menarini Group.